scholarly journals The Clinical Characteristics, Perioperative Management, and Treatment Outcomes of Spinal Tuberculosis Associated With Diabetes Mellitus

2021 ◽  
Author(s):  
Hongqi Zhang ◽  
Lige Xiao ◽  
Mingxing Tang ◽  
Yang Sun ◽  
Guanteng Yang
Keyword(s):  
Diabetes Mellitus ◽  
Postoperative Complications ◽  
Clinical Characteristics ◽  
Perioperative Management ◽  
Spinal Tuberculosis ◽  
Newly Diagnosed ◽  
Intraoperative Blood Loss ◽  
Group A ◽  
Group B

Abstract Background. Diabetes mellitus (DM) is a chronic systemic disorder that mainly damages small blood vessels and nerves. Previous studies indicate that DM is a major risk factor for perioperative complications of spine surgeries, such as wound infection, prolonged operative time, longer hospitalization, and higher nonunion rates. However, to the best of our knowledge, no study has compared differences between spinal tuberculosis associated with diabetes mellitus (DMSTB) and non-DMSTB in terms of clinical characteristics, perioperative management, radiographic outcomes and surgical complications.Methods. We performed a retrospective study of 11 DMSTB patients who underwent surgical treatment between January 2014 and April 2018. We also reviewed 11 matching non-DMSTB patients. Matching characteristics included age, sex, and the range of bone destruction by spine tuberculosis. All patients underwent the same surgical procedure. For each patient, demographic information, including age, sex, residence, chief complaints, preoperative complications, the length of stay (LOS), and hospitalization expenses (USD), was reviewed. In addition, operation time, intraoperative blood loss, and postoperative complications were reviewed from digital medical records. Moreover, laboratory examination and radiographic assessments were conducted before operation and at 3-month follow-up/final follow-up (FFU).Results. A total of 22 patients were divided into two groups: Group A (DMSTB) and Group B (non-DMSTB). All patients in Group A were newly diagnosed with spinal tuberculosis, while 4 were newly diagnosed with DM. The remaining 7 patients had been diagnosed with DM for an average of 6.15 ±5.87 yrs. The lumbar and lumbosacral regions were the most affected regions for 6 patients. Significant differences in residence (p=0.02) and preoperative complications (p=0.002) were found between Groups A and B. There were no differences in operation times (292.72±56.74 vs. 281.81±46.28 min, p=0.64), intraoperative blood loss levels (627.27±486.34 vs. 668.18±350.50 ml, p=0.83), hospitalization expenses ($19713.13±5816.89 vs. $16509.78±3170.89, p=0.14), or LOS periods (25.54±4.65 vs. 27.63±10.79 days, p=0.58). There were no significant differences in erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) between Groups A and B at each time point: preoperation and at 3-month follow-up/FFU. The albumin level was lower than that in the normal stand in both groups preoperatively (35.82±4.22 vs. 37.7±2.57g/L, p=0.24) and returned to normal at FFU (42.67±2.91 vs. 43.26±2.48 g/L, p=0.63). The imaging analysis shows no significant differences in vertebral body destruction between Group A and Group B (1.45±0.75 vs. 1.31±0.71, p=0.68) with a similar fusion level (2.63±1.43 vs. 2.81±1.74, p=0.8). The bone fusion times for Groups A and B were measured as 10.27±3.01 months and 9.9±2.11 months, respectively (p=0.87). There were no significant differences in postoperative complications between the DMSTB and non-DMSTB groups (p=0.42).Conclusion. Our study demonstrates that DMSTB has a higher incidence of preoperative complications than non-DMSTB, which increases the difficulty of perioperative management for spinal tuberculosis. However, DMSTB does not significantly affect postoperative recovery as long as the glycemic level remains well controlled, nutritional supplementation is adequate, and antituberculosis treatment is sufficient.

Cisplatin, vinblastine, and mitoguazone chemotherapy for epidermoid and adenocarcinoma of the esophagus.

1987 ◽  
Vol 5 (8) ◽  
pp. 1143-1149 ◽  
Author(s):  
A A Forastiere ◽  
M Gennis ◽  
M B Orringer ◽  
F P Agha
Keyword(s):  
Pilot Trial ◽  
Transhiatal Esophagectomy ◽  
Newly Diagnosed ◽  
Surgical Specimen ◽  
Carcinoma Of The Esophagus ◽  
Group A ◽  
Tumor Measurements ◽  
Regional Disease ◽  
Group B

Thirty-six patients with adenocarcinoma or epidermoid carcinoma of the esophagus were entered into a phase II trial evaluating the combination of cisplatin 100 mg/m2 intravenously (IV) day 2, vinblastine 1.6 mg/m2 IV days 1 to 4, and mitoguazone (MGBG) 500 mg/m2 IV days 1 and 8. Twenty-nine patients (group A) were newly diagnosed with local-regional disease only and were candidates for transhiatal esophagectomy (THE). These patients received two courses of chemotherapy at 3-week intervals prior to surgery. Response was assessed by measuring changes in the primary tumor length and depth on serial biphasic contrast esophagrams and comparing this result with tumor measurements obtained from the surgical specimen. Complete (CR) and partial responders (PR) received three additional postoperative cycles. Seven patients had recurrent or metastatic disease (group B) and were treated every 4 weeks until disease progression. Of 34 patients evaluable for response, there was one pathologically confirmed CR and 15 PRs (47%). This consisted of 12 of 27 (44%) group A patients (seven of 11 epidermoid, five of 16 adenocarcinoma) and four of seven (57%) group B patients (two of four epidermoid, two of three adenocarcinoma). Toxicity included leukopenia in one third of treatment courses and thrombocytopenia in 21%. Nausea and vomiting occurred in 60% of patients, diarrhea in 18%, transient nephrotoxicity in 18%, peripheral neuropathy in 12%, and ototoxicity in 3%. Twenty-five group A patients underwent resection. Four chemotherapy nonresponders (NR) and one PR had known disease left at surgery; all others (80%) had gross total removal of their disease. The median survival time (MST) of the 29 group A patients was 14 months, with 21% alive at 36 months. The MST of group A chemotherapy responders was 15 months compared with 9 months for NRs (P = .032). Initial sites of recurrence in 14 patients were local-regional in six, distant only in six, both local-regional and distant in two. This regimen, administered in maximally tolerated doses, was active in epidermoid and adenocarcinoma histologies, recurrent disease and newly diagnosed patients. However, nearly all responses were PRs and the MST of resected patients was similar to a prior series of patients treated with esophagectomy alone. Observations from this pilot trial and those of others have led to a follow-up study, in progress, evaluating intensive preoperative chemotherapy and concurrent radiation therapy (RT).

scholarly journals Comparison of conventional fenestration discectomy with Transforaminal endoscopic lumbar discectomy for treating lumbar disc herniation:minimum 2-year long-term follow-up in 1100 patients

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Quanyi Li ◽  
Yongchun Zhou
Keyword(s):  
Hospital Stay ◽  
Lumbar Disc ◽  
Length Of Hospital Stay ◽  
Bed Rest ◽  
Intraoperative Blood Loss ◽  
Postoperative Length ◽  
Group A ◽  
Group B ◽  
Endoscopic Lumbar Discectomy

Abstract Purpose To compare the efficacy of conventional interlaminar fenestration discectomy (IFD) with transforaminal endoscopic lumbar discectomy (TELD) for treating lumbar disc herniation (LDH). Methods The clinical data of 1100 patients who had been diagnosed with LDH between January 2012 and December 2017 were retrospectively analysed. IFD was performed on 605 patients in Group A, whereas TELD was performed on 505 patients in Group B. The Oswestry Disability Index, Visual Analogue Scale for pain and modified MacNab criteria were used to evaluate the outcomes. The surgery duration, intraoperative blood loss, postoperative off-bed activity and postoperative length of hospital stay were recorded. Results The follow-up period ranged from 24 to 60 months, with an average of 43 months. The excellent and good outcome rates were 93.5% in Group A and 92.6% in Group B. There was no significant difference in efficacy between the groups (P > 0.05). However, Group B had significantly less intraoperative blood loss and shorter bed rest duration and postoperative length of hospital stay than Group A (P < 0.05). There were two cases of postoperative recurrence in Group A and three in Group B. Conclusions Although conventional IFD and TELD had similar levels of efficacy in treating LDH, TELD had several advantages. There was less intraoperative bleeding, shorter length of hospital stay and shorter bed rest duration. It can be considered a safe and effective surgical option for treating LDH.

scholarly journals Clinical appraisal of Lodhradi Kashaya on type 2 diabetes mellitus patients

2017 ◽  
Vol 4 (1) ◽  
pp. 58
Author(s):  
Varun K. Singh ◽  
K. R. C. Reddy
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Dosage Form ◽  
Dose Group ◽  
Group A ◽  
Group B

<p class="abstract"><strong>Background:</strong> <span lang="EN-IN">Lodhradi Kashaya (LKSD) is basically ayurvedic kwath dosage form, described as Madhumehajeet (winner of diabetes mellitus) in ayurvedic classics Basavarajeeyam and the same formulation in Vaidya Chintamani and Charaka Samhita too. The aim of this study was to assess prospectively the drug’s ability in management of type 2 diabetes. </span></p><p class="abstract"><strong>Methods:</strong> <span lang="EN-IN">Total 31 patients were taken following the guideline mention in CCRAS protocol for diabetes mellitus research. They are divided into two groups, group A and B, given LKSD 4 g &amp; 2 g TDS respectively for three-month follow up. They are investigated against their blood glucose, HbA1C and liver profile tests. Patients were also investigated for subjective parameters viz polyurea, polyphagia, exhaustion and constipation and their response has also been noted regarding palatability acceptance and ease of administration.</span></p><p class="abstract"><strong>Results:</strong> <span lang="EN-IN">Patients has responded positively for formulation. Decrease in FBS and PPBS were found highly significant (P ˂ 0.001) in both groups but more in higher dose (group A). Decrease in HbA1C is also found highly significant in both groups. In LFT, SGOT level were also decreased more in group B in comparison to group A, and it is significant (P = 0.017 and 0.002). SGPT level were also decreased more in group B in comparison to group A, and it is significant in group B (P= 0.085 and 0.002).  </span></p><p class="abstract"><strong>Conclusions:</strong> LKSD is having astringent taste due to tannins and phenols in it. It was found significant not only in controlling blood sugar but also in management of other factors related to diabetes mellitus.</p>

scholarly journals Intramedullary nailing for pertrochanteric fractures of proximal femur: a consecutive series of 323 patients treated with two devices

2019 ◽  
Vol 14 (1) ◽  
Author(s):  
Pompeo Catania ◽  
Daniele Passaretti ◽  
Giorgio Montemurro ◽  
Simone Ripanti ◽  
Stefano Carbone ◽  
...  
Keyword(s):  
Blood Loss ◽  
Age Distribution ◽  
Harris Hip Score ◽  
Consecutive Series ◽  
Intraoperative Blood Loss ◽  
Pertrochanteric Fractures ◽  
Functional Scores ◽  
Group A ◽  
Group B

Abstract Introduction Pertrochanteric fractures (PFs) frequently affect the lower limb of osteoporotic patients and represent an important cause of morbidity and mortality in the elderly. In this prospective randomized controlled trial, we have compared functional and radiological results and complications of patients affected by PFs treated with two intramedullary proximal femoral nails. Materials We enrolled 323 subjects with PFs, classified according to AO/OTA system as 31.A1 (pertrochanteric simple) and 31.A2 (pertrochanteric multifragmentary). Patients were divided into two groups according to the osteosynthesis devices: group A, Elos-Intrauma® nail (155 cases) and group B, Gamma 3-Stryker® nail (168 cases). Pre-operatively, the baseline characteristics of each patient (gender, age, weight and BMI) were collected. Intraoperative blood loss, subjective pain by visual analogue scale (VAS), esthetic satisfaction, functional scores of the hip by Harris Hip Score (HHS), and Western Ontario and McMaster Universities Arthritis Index (WOMAC) were noted. The post-operative degree of fracture reduction was assessed. Each patient had a minimum follow-up of 12 months. Results The study group was composed of 106 male and 217 female with an average age of 85.4 (range, 65–90, standard deviation (SD) 5.95) years. No statistical differences about sex and age distribution were noted between the two groups. Group A reported lower intraoperative blood loss, 45 ml vs 51 ml, respectively (p < 0.001). There was not any statistical difference about operative time. Group A had a better reduction of fracture (p = 0.0347). The greatest difference was detectable comparing subgroups 31.A2 (p = 0.032). There were no statistical differences about complication frequency and the overall rate was 25% (80 cases). Finally, there was no difference in terms of VAS, HHS, and WOMAC score between the two groups on each follow-up. Patients of group A showed a higher subjective satisfaction index at 1 post-operative year, 7.42 (SD 1.19) vs 6.45 (SD 1.35) of group B (p < 0.001). Conclusion Elos® nail is a reliable device on a short-term follow-up and represents an alternative choice to the Gamma 3® nail, a well-known and appreciated system for over 25 years.

scholarly journals Pegaspargase Plus Gemcitabine, Oxaliplatin(P-Gemox) and Thalidomide Versus Aspermetdex Regimen for the Patients with Early or Advanced/Relapsed Extranodal Natural Killer/T Cell Lymphoma: Interim Analysis of a Prospective,Multicenter, Randomized, Phase III Non-Inferiority Clinical Trial

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 1819-1819
Author(s):  
Yan Gao ◽  
Huiqiang Huang ◽  
Yujing Zhang ◽  
Hang Su ◽  
Xiaoxiao Wang ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Stage I ◽  
Phase Iii ◽  
Stage Iii ◽  
Newly Diagnosed ◽  
Natural Killer T Cell ◽  
Group A ◽  
Group B ◽  
Killer T Cell

Abstract Backgroud and Purpose Extranodal natural killer/T-cell lymphoma (ENKTL) is an uncommon, aggressive form of non-Hodgkin's lymphoma. Optimal therapeutic strategies have not been fully defined yet. Both AsperMetDex and P-Gemox is recommended as major effective regimen by 2016 NCCN guideline. Therefore, we try to evaluate the efficacy and toxicity for P-Gemox plus thalidomide and AsperMetDex followed by EIFRT as first-line treatment for newly diagnosed stage I/II patients and as salvage regimen for newly diagnosed stage III/IV or relapsed/refractory ENKTL in this study. Patients and methods We initiated a prospective, multicentre, randomized, phase III ,non-inferiority clinical trial at 12 centers in China at March 2014. Patients were randomly assigned to receive either P-Gemox+thalidomide regimen (Group A: Pegaspargase 2000U/m2; im d1, Gemcitabine 1000mg/m2; ivdrip , d1, d8. Oxaliplatin 130mg/m2; ivdrip, d1, thalidomide 100mg/d po, for one year.) or AsperMetDex regimen(Group B: Pegaspargase 2000U/m2; im, d1, Methotrexate 3000mg/ m2; civ 6-hour, d1, calcium folinate 30mg iv, q6h, until reach safe serum MTX concentration, Dexamethasone 40mg/d ivdrip, d1-4.). For newly diagnosed stage I/II patients, both regimens were repeated every three weeks for a maximum four cycles as induction chemotherapy and followed by EIFRT at the dosage of 56Gy in 28 fractions over 4 weeks. Primary EIFRT was delivered using 6-MeV linear accelerator using 3-dimensional conformal treatment planning. For newly diagnosed stage III/IV or relapsed/refractory ENKTL, the regimens were repeated every three weeks for a maximum six cycles. Patients underwent autologous hematopoietic stem cell transplantation (ASCT) as consolidation if they achieved response (complete remission, CR or partial remission, PR). The primary endpoint was progression-free survival(PFS), with a non-inferiority margin of 15%. Results 110 patients were enrolled (56 patients in Group A, 54 in Group B) and 96 patients were evaluable for response. Among 63 newly diagnosed stage I/II patients, 32 patients were assigned to Group A (27 assessed), and 31 to Group B (27 assessed). At median follow-up of 13.5 months (IQR 0.5¨C27.5), 2-year PFS were 82.9%(95%CI:17.574-24.111) and 84.5% (95%CI:18.849- 25.688). 2-year OS were 95.0%(95%CI:13.023-22.896) and 75.8%(95%CI:11.647-21.269), P=0.089, (Figure1). CR rate of both group were all 59.3%(16/27), and objective response rate(ORR) were 85.2%(23/27) and 81.5%(16/27), respectively. After EIFRT, ORR of Group A increased to 92.6% (25/27), CR rate was 88.8% (24/27). ORR of Group B increased to 88.8% (24/27), CR rate was 85.1% (23/27). For 47 newly diagnosed stage III/IV or relapsed/refractory patients, 24 patients were assigned to Group A (22 assessed) and 23 to Group B (20 assessed). At median follow-up of 14.5 months (IQR 0.6¨C28.1), median PFS was longer in the Group A than Group B(12.2 vs. 7.6 months, P=0.365). 2-year OS were 52.5%(95%CI:13.023-22.896) and 48.9% (95%CI:11.647- 21.269), P=0.935 (Figure2). The ORR were 86.4%(19/22) and 70%(14/20), respectively. CR rate were similar for both group with 50%. Six cases (3 cases in each group ) had received ASCT after response, 3 patients relapsed in 6 months after ASCT(2 cases in group A, 1 case in group B) , 2 patients died of disease progression. Group B was better tolerated than Group A, with lower rates of agranulocytosis, thrombocytopenia and infections. While anemia, hyperbilirubinemia, edema, and increased BUN/Cr were more common in Group B. Three patients died of treatment related toxicity only in Group B. Two patients died of severe acute renal failure and sepsis at the first cycle, and one patient died of sepsis at the third cycle (Table 1). Median hospitalization time were 1.9 days for Group A and 4.9 days for Group B(P<0.01), respectively. CONCLUSION: Induction chemotherapy of both P-Gemox+Thalidomide and AsperMetDex regimen followed by ENKTL yielded promising efficacy for patients with stage I/II ENKTL. For advanced or relapsed patients, both regimen showed unsatisfied survival outcome. Meanwhile, P-Gemox+ Thalidomide may be less toxic with more simple and convenient administration in outpatients clinics in comparison to AsperMetDex. This clinical trial is still ongoing . (ClinicalTrials.gov, NCT 2085655). Funding: 5010 Program for Clinical Research , Sun Yat -Sen University. Disclosures No relevant conflicts of interest to declare.

scholarly journals The Clinical Characteristics, Perioperative Management, and Treatment Outcomes of Spinal Tuberculosis Associated With Diabetes Mellitus

2021 ◽  
Author(s):  
Hongqi Zhang ◽  
Lige Xiao ◽  
Mingxing Tang ◽  
Yang Sun ◽  
Guanteng Yang
Keyword(s):  
Diabetes Mellitus ◽  
Surgical Treatment ◽  
Perioperative Management ◽  
Spinal Tuberculosis ◽  
Perioperative Period ◽  
Demographic Information ◽  
Antituberculosis Treatment ◽  
Strategic Factors ◽  
Patient Demographic Information

Abstract Background. To report a preliminary experience of surgical treatment for patients with spinal tuberculosis (STB) associated with diabetes mellitus (DM) and discuss the strategic factors that should be considered.Methods. A retrospective study of DMSTB patients who underwent surgical treatment between January 2012 and April 2018 in our center was carried out. For each patient: demographic information, perioperative management, laboratory examination, radiographic assessments, and clinical outcomes were reviewed.Results. A total of 17 patients were included (11 males and 6 females), with a mean age of 57.53±9.25 years and a follow-up of 28±3.00 mos. Hypertension, Osteoporosis, and Hypoproteinemia were the most common complication. All patients passed the perioperative period smoothly, the 3 months follow-up showed the CRP and ESR have a significant decline, and the final follow-up shows both CRP and ESR back to normal, and there were a significant improvement of serum albumin levels. The Bone fusion time is 9.88±2.65 mos.Conclusions. Perioperative management of DMSTB patients is a complicated issue with numerous factors to be considered. Spinal surgery can achieve satisfactory outcomes in these patients if the glycemic level remains well controlled, nutritional supplementation is adequate, and antituberculosis treatment is sufficient.

scholarly journals Comparison of single posterior debridement, bone grafting, and instrumentation with single anterior debridement, bone grafting, and instrumentation in treatment of thoracic spinal tuberculosis

2019 ◽  
Author(s):  
Yongchun Zhou ◽  
Weiwei Li ◽  
Liqun Gong ◽  
Jiao Zhou ◽  
Jing Luo
Keyword(s):  
Bone Grafting ◽  
Spinal Tuberculosis ◽  
Operation Time ◽  
Anterior Debridement ◽  
Thoracic Spinal ◽  
Group A ◽  
Group B ◽  
Posterior Debridement ◽  
Thoracic Spinal Tuberculosis

Abstract Objective To explore the clinical effect of single posterior debridement, bone grafting, and instrumentation and single anterior debridement, bone grafting and instrumentation in the treatment of thoracic spinal tuberculosis of adult patients. Methods: A retrospective analysis was made by involving 38 adult patients with thoracic spinal tuberculosis from between June 2013 and December 2015. Of the 38 patients, 21 patients were categorized in single anterior approach group and underwent single posterior debridement, bone grafting, and instrumentation (Group A). The remaining 17 patients were classified in single posterior approaches group (Group B), which received single posterior debridement, bone grafting and instrumentation. Clinical manifestations, laboratory and imaging results of the two groups were analyzed subsequently. Results: All patients were followed up for 23.9 ± 3.8 m (range, 19–36 m). Bony fusion was achieved in all bone grafts. The operation time and intraoperative blood loss in group B were significantly less than those in group A (P<0.05). The VAS scores, ESR, and CRP levels 6 weeks after operation and at the final follow-up were significantly lower than the preoperative levels (P<0.05). At the last follow-up, ASIA improvement no significant difference between groups (P>0.05). Furthermore, the postoperative and final-follow-up kyphosis angles in group B were both significantly smaller than those in group A (P<0.05). Group A had a postoperative angle correction rate smaller than group B, and its postoperative angle loss was greater than group B’s (P<0.05). Conclusion: Single posterior debridement, bone grafting, and instrumentation can achieve similar curative effect as single anterior debridement, bone grafting and instrumentation in the treatment of thoracic spinal tuberculosis, but also accompanied by additional advantages of shorter operation time and less bleeding .

Bevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma: Update progression-free survival, overall survival, and toxicity

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 2017-2017 ◽  
Author(s):  
M. L. Gruber ◽  
S. Raza ◽  
D. Gruber ◽  
A. Narayana
Keyword(s):  
Overall Survival ◽  
Progression Free Survival ◽  
Newly Diagnosed ◽  
Similar Treatment ◽  
Macdonald Criteria ◽  
Newly Diagnosed Glioblastoma ◽  
Group A ◽  
Group B ◽  
Cycle Group

2017 Background: Prognosis of glioblastoma (GBM) is very poor. Standard treatment includes surgical resection (SR), radiation (RT), concomitant and adjuvant chemotherapy with temozolomide (TMZ). Our objective is to assess the treatment efficacy, safety and survival in patients with newly-diagnosed GBM treated with RT, TMZ, and bevacizumab in the upfront management. Methods: From 2006–2008, 51 eligible patients (age >18, KPS >70) with newly-diagnosed GBM divided into two groups. Group A (n = 20) was treated with RT (60Gy) and concomitant TMZ (75mg/m2 daily for 42 days) with bevacizumab (10mg/kg every 2 weeks), 29 days following surgery, followed by up to six cycles of adjuvant TMZ (150mg/m2,daily x 7d, q28 with bevacizumab at 10mg/kg days 8 and 22 of each 28 day cycle. Group B (n = 31) received similar treatment without bevacizumab. Both groups were followed up until tumor progression (PFS). Recurrence was defined according to MacDonald Criteria. The end points were PFS, overall survival (OS) and toxicity. Results: Median bevacizumab infusions were 12 (4–32). Median follow-up was14 months for both groups. 6 months PFS survival in Group A was 77.5% and in Group B was 51.6%. Median PFS in Group A was 17 months compared to 7 months in Group B (p < 0.0001, HR = 0.26). Median OS has not been reached in Group A and was 17 months in Group B. One and 2 year OS were 83% and 57% in Group A compared to 72% and 6.5% in Group B (p = 0.02) ). Post-RT and temodar toxicities include thrombocytopenia (1 patient; Gr 3 and fatigue (3 patient;1 Gr 3), bevacizumab related toxicities with RT include leg ulcer with cellulites (1 patient; Gr 3) and pulmonary embolism with thrombocytopenia (1 patient; Gr 4), hypertension (2 patients; Gr 1), and asymptomatic blood products on MRI (2 patients). Conclusions: Bevacizumab has demonstrated efficacy, acceptable toxicity, improved PFS and OS in the upfront management of GBM. No significant financial relationships to disclose.

scholarly journals Effect on serum potassium level in patients of diabetic nephropathy on spironolactone and ramipril over follow up period

2019 ◽  
Vol 7 (12) ◽  
pp. 4691
Author(s):  
Ashish Naresh ◽  
Mahendra Pal Singh ◽  
Richa Giri
Keyword(s):  
Diabetes Mellitus ◽  
Diabetic Nephropathy ◽  
Serum Potassium ◽  
Potassium Level ◽  
Serum Potassium Level ◽  
P Value ◽  
Base Line ◽  
Group A ◽  
Group B

Background: The study was conducted to evaluate the change in serum potassium level over follow up period in patients of diabetic nephropathy on spironolactone (25 mg) and ramipril (5 mg) and compare the results with diabetic nephropathy patients on Spironolactone (25 mg) alone.Methods: A comparative, prospective, non-randomized, non-blinded experimental study was conducted on 56 patients (30-70 yr.) of diagnosed type 2 diabetes mellitus showing proteinuria. Total duration of study was about one year from October 2017 to October 2018. Inclusion criteria followed in study were Age 30-70 years, diagnosed type 2 diabetes mellitus, serum potassium level <5 meq/l, estimated GFR >30 ml/min/1.73m2 and HbA1c <10%. Exclusion criteria were type 1 diabetes mellitus, impaired glucose tolerance secondary to endocrine disease, exocrine pancreatic disease, SBP >180 mmHg DBP >110 mmHg, UTI, hematuria, acute febrile illness, vigorous exercise, short-term pronounced hyperglycemia, obstructive uropathy, confirmed or suspected renal artery disease by USG doppler study, Serum potassium level >5.5 meq/l. Patients were divided in two groups, group A (n= 28, spironolactone 25 mg and ramipril 5 mg) and group B (n=27, spironolactone 25 mg). Subjects were followed over 12 weeks and baseline and 12-week serum potassium being compared. Other baseline base line laboratory investigation such as serum lipid profile, HbA1c, eGFR, fundus examination, ultrasonography (KUB), serum urea, serum creatinine, hemoglobin, were taken at the starting point.Results: Both the group after receiving respective drug were followed for 3-month duration and serum potassium level measured at end of 3 months. Mean values of baseline and follow up serum potassium for group A and group B were 4.24±0.59, 4.07±0.61 and 4.35±0.55, 4.16±0.61 respectively, p value found to be >0.05 at 95% CI.Conclusions: In the study it was concluded that p value found to be >0.05 at 95% C.I denoting that there is no significant difference between mean value of base line and follow up serum potassium value in both group. None of patients in either group had experienced hyperkalaemia over follow up period though serum potassium level were slightly higher in group A, but this difference was statistically not significant. Follow up period of study should be long enough to comment on safety profile of combining spironolactone and ACE inhibitors in diabetic nephropathy patients.

Outcome of Single Stage OMG Urethroplasty by Kulkarni Technique in Comparison With Johanson’s Staged Urethroplasty for Management of Pan-Urethral Stricture

2020 ◽  
Vol 19 (2) ◽  
pp. 78-84
Author(s):  
Md Shariful Islam ◽  
Md Asaduzzamman ◽  
Kaiser Ahmed ◽  
MA Salam ◽  
Md Shawkat Alam
Keyword(s):  
Postoperative Complications ◽  
Clinical Outcome ◽  
Urethral Stricture ◽  
Operative Procedure ◽  
Single Stage ◽  
Buccal Mucosal Graft ◽  
Group A ◽  
Group B ◽  
Final Calculation

Purpose: To observe the outcome of single stage buccal mucosal graft and Johanson’s staged urethroplasty for treatment of pan- urethral stricture. Materials and Methods: A total of 60 patients with an average age of 42 years (21-55) underwent OMG urethroplasty and Johanson’s staged urethroplasty between March 2008 to September 2015 for pan-urethral stricture of different etiology. OMG was always harvested from cheek using 2 team approaches. Graft was placed using Kulkarni technique. Clinical outcome was considered success or failure if any post operative procedure needed. Mean follow up was 45 month (6-95) Results: Total 60 patients were included for final calculation, 31 patients with buccal mucosal graft (Group A) and 29 patients with Johanson’s staged urethroplasty (Group B) were followed up for average 45 months. Success rate of group A was 93.5% at 3 months and 77.4% at 3 years and in group B 65.5% at 3 months and 44.8% at 3 years follow up which is statiscally significant (p <.05). Postoperative complications were significantly higher in group-B. Conclusion: Repair of pan-urethral stricture in a single-stage OMG by Kulkarni technique is simple, fast, safe, effective and reproducible in the hand of any surgeon. Bangladesh Journal of Urology, Vol. 19, No. 2, July 2016 p.78-84

Sign in / Sign up

Export Citation Format

Share Document